Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Argenx Acquires Forte Biosciences to Accelerate CD122‑Targeted Autoimmune Therapies

Argenx’s acquisition of Forte Biosciences boosts its autoimmune pipeline with the promising CD122 antibody FB102, offering a novel cytokine‑receptor approach to treat vitiligo and coeliac disease.

Dr. Michael Chen

30/07/2026, 07:27

4 minutes to read

Danaher Q2 Earnings: Life Sciences & Diagnostics Surge, Boosting Investor Confidence

Danaher’s Q2 shows 12% life‑sciences and 10% diagnostics revenue growth, fueling a 6% EPS rise and bolstering investor confidence with a strong R&D pipeline.

Dr. Michael Chen

29/07/2026, 19:11

4 minutes to read

Alnylam Strengthens RNAi Innovation with Dr. Laura Sepp‑Lorenzino on Its Advisory Board

Alnylam strengthens its RNA‑medicine pipeline by adding Dr. Laura Sepp‑Lorenzino to the Scientific Advisory Board, boosting CRISPR‑RNAi expertise and clinical‑trial strategy.

Dr. Michael Chen

29/07/2026, 15:00

3 minutes to read

West Pharmaceutical Services Joins Income‑Focused ETFs, Boosting Dividend Appeal and Pharma Innovation

West Pharmaceutical Services shines in income‑focused ETFs, delivering stable dividends and cutting‑edge drug delivery tech for biopharma.

Dr. Michael Chen

26/07/2026, 22:06

3 minutes to read

Top Pharma Firms Outperform: Patent Strategy, Pipeline Depth & ROI Explained

Discover which pharma giants dominate the market by mastering patents, pipeline depth, and clinical proof—insights for investors seeking long‑term value.

Dr. Michael Chen

26/07/2026, 20:25

5 minutes to read

Eurofins Surpasses Half‑Year Targets, Boosts Growth With $400M Life Sciences Acquisition

Eurofins Scientific beats Q1 earnings expectations, drives €3.12 bn revenue growth with strategic acquisitions and a focus on biopharma testing.

Dr. Michael Chen

25/07/2026, 09:23

2 minutes to read

How Bayer’s July Rally, Self‑Care Research, and Strong Compliance Drive Investor Confidence

Discover how Bayer AG’s July share rally, self‑care research, and regulatory diligence are reshaping chronic disease treatment and investor confidence.

Dr. Michael Chen

24/07/2026, 13:04

4 minutes to read

Novo Nordisk Launches Oral GLP‑1 Weight‑Loss Tablet, Boosting Market Reach

Discover how Novo Nordisk’s new oral GLP‑1 tablet transforms obesity treatment, boosting patient adherence, clinical outcomes, and investor confidence.

Dr. Michael Chen

23/07/2026, 17:01

4 minutes to read

DAIICHI SANKYO Joins Noetra Corp. AI Consortium to Build Japan’s Sovereign Foundation Model

DAIICHI Sankyo joins Japan’s Noetra Corp AI consortium to build a sovereign multimodal foundation model, boosting industrial automation, predictive maintenance, and regulatory compliance for robotics.

Dr. Michael Chen

20/07/2026, 12:08

4 minutes to read

Genmab & Merus Launch INCA33890: Dual TGFβR2‑PD‑1 Bispecific for MSS Colorectal Cancer

Genmab and Merus launch bispecific INCA33890, targeting TGFβR2 and PD‑1 to turn “cold” MSS colorectal cancers “hot,” promising a new immunotherapy option.

Dr. Michael Chen

19/07/2026, 15:53

3 minutes to read